ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1877

Cisplatin-Induced AKI Cancer Mouse Model Refinement

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Thompson, Lauren E., University of Colorado Health, Aurora, Colorado, United States
  • McGinnis, Courtney D., University of Colorado Health, Aurora, Colorado, United States
  • Edelstein, Charles L., University of Colorado Health, Aurora, Colorado, United States
  • Joy, Melanie S., University of Colorado Health, Aurora, Colorado, United States
Background

Cisplatin (CIS), a common chemotherapeutic, causes acute kidney injury (AKI) in up to one-third of patients. Traditional mouse models use healthy mice and a single, lethal dose of CIS (20-30 mg/kg). This model does not accurately reflect the clinical use of CIS where cancer patients receive 25-100 mg/m2 once every 3-4 weeks. There is a need for a multi-dose mouse cancer model of CIS-AKI that more closely reflects CIS clinical use.

Methods

C57BL/6 male mice (8 weeks old; n=45) were injected in the right flank with murine lung cancer cells (CMT167; 0-1,500,00 cells). Subcutaneous solid tumors were allowed to grow for ~2 weeks until digital caliper measurement confirmed they were ≥50 mm3. Mice were then dosed with CIS (0, 12.5, 15 mg/kg) or vehicle (saline) 1x/week for up to 4 weeks. Mice were evaluated for outcomes of general health (body weight), survival, cancer progression (tumor volume), and kidney injury (SCr, BUN, KIM-1). Assessments were performed ≥1x/week until sacrifice after 1-4 weeks of CIS treatment. Analyses for differences from baseline to sacrifice based on both cancer cells injected and CIS dose were assessed by 2-way ANOVA with a Tukey-Kramer post-hoc test. p<0.05 was considered statistically significant.

Results

Groups injected with >1 million CMT167 cells experienced the greatest decline in survival due to rapid tumor growth and ulceration (0% at 8 d). Cancer-free mice treated with CIS also experienced poor survival due to dehydration and weight loss (60% at 15 d). Mice injected with 50,000 CMT167 cells had the best survival (100% at 13 d). Body weight was significantly decreased as CIS dose increased (p=1.9*10-8) and increased as number of CMT167 cells increased (p=5.5*10-8). Tumor volume was significantly increased as number of CMT167 cells increased (p=5.1*10-5) and somewhat decreased as CIS dose increased (p=0.092). CIS dose did not significantly impact BUN or SCr levels but an increase in KIM-1 was somewhat associated with an increased CIS dose (p=0.105; 12.5 vs 15 mg/kg CIS p=0.191). There were no significant differences in body weight, tumor volume, or survival between the 12.5 and 15 mg/kg CIS treated mice.

Conclusion

The results indicate that the ideal CMT167 mouse cancer model of CIS-AKI should use 50,000 CMT167 cells and 15 mg/kg CIS. This model can be used to better understand CIS-AKI and to test potential protective compounds.

Funding

  • Other NIH Support